The FDA agreed with Vanda's position that motion sickness is an acute, self-limiting physiologic response rather than a chronic or chronic-intermittent condition. The Agency there ...
Tradipitant could become the first new pharmacologic treatment for motion sickness in over 40 years.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced the following updates regarding tradipitant for motion ...
FDA accelerates re-review of Vanda's tradipitant and begins label talks, keeping its motion sickness drug on track for key 2025 decisions.
Vanda Pharmaceuticals and the FDA have agreed to lay down their swords, squashing years of legal disputes with an agreement that will see regulatory action on much of Vanda’s grievances. The ...
Update 11:15am: Adds Vanda response, updates shares. Vanda Pharmaceuticals (NASDAQ:VNDA) jumped 11% after Cycle Pharmaceuticals reaffirmed its $8/share all cash offer for the company. "Cycle is making ...
Vanda Pharmaceuticals (VNDA) delivered its third quarter 2025 earnings report, highlighting 18% revenue growth and strong Fanapt sales. The company also refined its revenue outlook while advancing key ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback